Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2013

Open Access 01-12-2013 | Research article

Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study

Authors: Paolo A Cortesi, Claudio Mencacci, Ferrannini Luigi, Elvezio Pirfo, Patrizia Berto, Miriam CJM Sturkenboom, Fabiana L Lopes, Maria G Giustra, Lorenzo G Mantovani, Luciana Scalone

Published in: BMC Psychiatry | Issue 1/2013

Login to get access

Abstract

Background

Little data is available on the real-world socio-economic burden and outcomes in schizophrenia. This study aimed to assess persistence, compliance, costs and Health-Related Quality-of-Life (HRQoL) in young patients undergoing antipsychotic treatment according to clinical practice.

Methods

A naturalistic, longitudinal, multicentre cohort study was conducted: we involved 637 patients aged 18–40 years, with schizophrenia or schizophreniform disorder diagnosed ≤10 years before, enrolled in 86 Italian Mental Health Centres and followed-up for 1 year. Comparisons were conducted between naïve (i.e., patients visiting the centre for the first time and starting a new treatment regimen) and non naïve patients.

Results

At enrolment, 84% of patients were taking atypical drugs, 3.7% typical, 10% a combination of the two classes, and 2% were untreated. During follow-up, 23% of patients switched at least once to a different class of treatment, a combination or no treatment. The mean Drug-Attitude-Inventory score was 43.4, with 94.3% of the patients considered compliant by the clinicians. On average, medical costs at baseline were 390.93€/patient-month, mostly for drug treatment (29.5%), psychotherapy (29.2%), and hospitalizations (27.1%). Patients and caregivers lost 3.5 days/patient-month of productivity. During follow-up, attitude toward treatment remained fairly similar, medical costs were generally stable, while productivity, clinical statusand HRQoL significantly improved. While no significantly different overall direct costs trends were found between naïve and non naïve patients, naïve patients showed generally a significant mean higher improvement of clinical outcomes, HRQoL and indirect costs, compared to the others.

Conclusions

Our results suggest how tailoring the treatment strategy according to the complex and specific patient needs make it possible to achieve benefits and to allocate more efficiently resources. This study can also provide information on the most relevant items to be considered when conducting cost-effectiveness studies comparing specific alternatives for the treatment of target patients.
Appendix
Available only for authorised users
Literature
1.
2.
McGlashan TH: A selective review of recent North American long-term followup studies of schizophrenia. Schizophr Bull. 1988, 14 (4): 515-542. 10.1093/schbul/14.4.515.CrossRefPubMed
3.
4.
Rössler W, Salize HJ, van Os J, Riecher-Rössler A: Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol. 2005, 15 (4): 399-409. 10.1016/j.euroneuro.2005.04.009.CrossRefPubMed
5.
Mueser K, McGurk S: Schizophrenia. Lancet. 2004, 363 (9426): 2063-2072. 10.1016/S0140-6736(04)16458-1.CrossRefPubMed
6.
Knapp M, Mangalore R, Simon J: The global costs of schizophrenia. Schizophr Bull. 2004, 30 (2): 279-293. 10.1093/oxfordjournals.schbul.a007078.CrossRefPubMed
7.
Stargardt T, Edel MA, Ebert A, Busse R, Juckel G, Gericke CA: Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany. J Clin Psychopharmacol. 2012, 32 (5): 602-607. 10.1097/JCP.0b013e318268ddc0.CrossRefPubMed
8.
Phanthunane P, Whiteford H, Vos T, Bertram M: Economic burden of schizophrenia: empirical analyses from a survey in Thailand. J Ment Health Policy Econ. 2012, 15 (1): 25-32.PubMed
9.
Sarlon E, Heider D, Millier A, Azorin JM, König HH, Hansen K, Angermeyer MC, Aballéa S, Toumi M: A prospective study of health care resource utilisation and selected costs of schizophrenia in France. BMC Health Serv Res. 2012, 12: 269-276. 10.1186/1472-6963-12-269.CrossRefPubMedPubMedCentral
10.
Chang SM, Cho SJ, Jeon HJ, Hahm BJ, Lee HJ, Park JI, Cho MJ: Economic burden of schizophrenia in South Korea. J Korean Med Sci. 2008, 23 (2): 167-175. 10.3346/jkms.2008.23.2.167.CrossRefPubMedPubMedCentral
11.
Terkelsen KG, Menikoff A: Measuring the costs of schizophrenia. Implications for the post-institutional era in the US. PharmacoEconomics. 1995, 8 (3): 199-222. 10.2165/00019053-199508030-00004.CrossRefPubMed
12.
13.
Fitzgerald PB, Montgomery W, de Castella AR, Filia KM, Filia SL, Christova L, Jackson D, Kulkami J: Australian Schizophrenia Care and Assessment Programme: real-world schizophrenia: economics. Aust N Z J Psychiatry. 2007, 41 (10): 819-829. 10.1080/00048670701579025.CrossRefPubMed
14.
Oliva-Moreno J, López-Bastida J, Osuna-Guerrero R, Montejo-González AL, Duque-González B: The costs of schizophrenia in Spain. Eur J Health Econ. 2006, 7 (3): 182-188.CrossRefPubMed
15.
Mangalore R, Knapp M: Cost of schizophrenia in England. J Ment Health Policy Econ. 2007, 10 (1): 23-41.PubMed
16.
Davies LM, Drummond MF: Economics and schizophrenia: the real cost. Br J Psychiatry Suppl. 1994, 25: 18-21.PubMed
17.
Alonso J, Croudace T, Brown J, Gasquet I, Knapp MR, Suárez D, Novick D: Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study. Value Health. 2009, 12 (4): 536-543. 10.1111/j.1524-4733.2008.00495.x.CrossRefPubMed
18.
Kilian R, Angermeyer MC: The effects of antipsychotic treatment on quality of life of schizophrenic patients under naturalistic treatment conditions: an application of random effect regression models and propensity scores in an observational prospective trial. Qual Life Res. 2005, 14 (5): 1275-1289. 10.1007/s11136-004-5533-x.CrossRefPubMed
19.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. NEngl J Med. 2005, 353 (12): 1209-1223. 10.1056/NEJMoa051688.CrossRef
20.
Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE, EUFEST study group: Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008, 371 (9618): 1085-1097. 10.1016/S0140-6736(08)60486-9.CrossRefPubMed
21.
Tiihonen J, Wahlbeck K, Lönnqvist J, Klaukka T, Ioannidis JP, Volavka J, Haukka J: Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 2006, 333 (7561): 224-10.1136/bmj.38881.382755.2F.CrossRefPubMedPubMedCentral
22.
Malla AK, Norman RM, Joober R: First-episode psychosis, early intervention, and outcome: what have we learned?. Can J Psychiatry. 2005, 50 (14): 881-891.PubMed
23.
Perkins D, Lieberman J, Gu H, Tohen M, McEvoy J, Green A, Zipursky R, Strakowski S, Sharma T, Kahn R, Gur R, Tollefson G, HGDH Research Group: Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry. 2004, 185: 18-24. 10.1192/bjp.185.1.18.CrossRefPubMed
24.
Strakowski SM, Johnson JL, Delbello MP, Hamer RM, Green AI, Tohen M, Lieberman JA, Glick I, Patel JK, HGDH Research Group: Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schizophr Res. 2005, 78 (2–3): 161-169.CrossRefPubMed
25.
Amminger GP, Henry LP, Harrigan SM, Harris MG, Alvarez-Jimenez M, Herrman H, Jackson HJ, McGorry PD: Outcome in early-onset schizophrenia revisited: findings from the Early Psychosis Prevention and Intervention Centre long-term follow-up study. Schizophr Res. 2011, 131 (1–3): 112-119.CrossRefPubMed
26.
Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T: Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ. 2013, 346: f185-10.1136/bmj.f185.CrossRefPubMedPubMedCentral
27.
Marshall M, Rathbone J: Early intervention for psychosis (review). Cochrane Database. Syst Rev. 2011, 6: CD004718-PubMed
28.
Gafoor R, Nitsch D, McCrone P, Craig TK, Garety PA, Power P, McGuire P: Effect of early intervention on 5-year outcome in non-affective psychosis. Br J Psychiatry. 2010, 196 (5): 372-376. 10.1192/bjp.bp.109.066050.CrossRefPubMed
29.
Andreoli V, Cassano GB, Rossi R: Manuale diagnostico e statistico dei disturbi mentali (DSM-IV-TR), italian translation. 2001, Milano: MassonSpA,
30.
31.
Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987, 13 (2): 261-276. 10.1093/schbul/13.2.261.CrossRefPubMed
32.
Pancheri P, Brugnoli R, Carilli L, Marconi PL, Petrucci RM: Valutazione dimensionale della sintomatologia schizofrenica. Validazione della versione italiana della Scala per la valutazione dei Sintomi Positivi e Negativi (PANSS). Giorn Ital Psicopat. 1995, 1: 60-75.
33.
Guy G: Clinical Global Impression. ECDEU assessment manual for psychopharmacology, revised. 1976, Rockville (MD: National Institute of Mental Health
34.
Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, Rodríguez MJ, Rele R, Orta J, Kharbeng A, Araya S, Gervin M, Alonso J, Mavreas V, Lavrentzou E, Liontos N, Gregor K, Jones PB, SOHO Study Group: The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl. 2003, 416: 16-23.CrossRefPubMed
35.
Endicott J, Spitzer RL, Fleiss JL, Cohen J: The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976, 33: 766-771. 10.1001/archpsyc.1976.01770060086012.CrossRefPubMed
36.
Rabin R, de Charro F: EQ-5D: a measure of health status from the EuroQolGroup. Ann Med. 2001, 33 (5): 337-343. 10.3109/07853890109002087.CrossRefPubMed
37.
Ware J, Kosinski M, Keller SD: SF-36 Physical and Mental Health Summary Scales: A User’s Manual. 1994, Boston (MA): The Health Institute
38.
Pukrop R, Schlaak V, Moller-Leimkuhler AM, Albus M, Czernik A, Klosterkötter J, Möller HJ: Reliability and validity of Quality of Life assessed by the Short-Form 36 and the Modular System for Quality of Life in patients with schizophrenia and patients with depression. Psychiatry Res. 2003, 119 (1–2): 63-79.CrossRefPubMed
39.
König HH, Roick C, Angermeyer MC: Validity of the EQ-5D in assessing and valuing health status in patients with schizophrenic, schizotypal or delusional disorders. Eur Psychiatry. 2007, 22 (3): 177-187. 10.1016/j.eurpsy.2006.08.004.CrossRefPubMed
40.
Prieto L, Novick D, Sacristán JA, Edgell ET, Alonso J, SOHO Study Group: A Rasch model analysis to test the cross-cultural validity of the EuroQoL-5D in the Schizophrenia Outpatient Health Outcomes Study. Acta Psychiatr Scand Suppl. 2003, 416: 24-29.CrossRefPubMed
41.
Prieto L, Sacristán JA, Hormaechea JA, Casado A, Badia X, Gómez JC: Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients. Curr Med Res Opin. 2004, 20 (6): 827-835. 10.1185/030079904125003674.CrossRefPubMed
42.
Badia X, Montserrat R, Herdman M, Kind P: A comparison of United Kingdom and Spanish General Population Time Trade-Off Values for EQ-5D Health States. Med Decis Making. 2001, 21: 7-16. 10.1177/0272989X0102100102.CrossRefPubMed
43.
Ware JE, Gandek B, Kosinski M, Aaronson NK, Apolone G, Brazier J, Bullinger M, Kaasa S, Leplège A, Prieto L, Sullivan M, Thunedborg K: The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998, 51 (11): 1167-1170. 10.1016/S0895-4356(98)00108-5.CrossRefPubMed
44.
Hogan TP, Awad AG, Eastwood R: A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983, 13: 177-183. 10.1017/S0033291700050182.CrossRefPubMed
45.
Rossi A, Arduini L, de Cataldo S, Stratta P: Subjective response to neuroleptic medication: a validation study of the Italian version of the drug attitude inventory (DAI). Epidemiol Psichiatr Soc. 2001, 10: 107-114. 10.1017/S1121189X00005182.CrossRefPubMed
46.
47.
48.
49.
50.
Drummond MF, Shulpher MJ, Torrance GW, O’Brein B, Stoddart GL: Methods for the economic evaluation of health care programmes. 1986, Oxford England: Oxford University Press, 3 (2005)
51.
Grover S, Avasthi A, Chakrabarti S, Bhansali A, Kulhara P: Cost of care of schizophrenia: a study of Indian out-patient attenders. Acta Psychiatr Scand. 2005, 112 (1): 54-63. 10.1111/j.1600-0447.2005.00512.x.CrossRefPubMed
52.
53.
Serretti A, Mandelli L, Bajo E, Cevenini N, Papili P, Mori E, Bigelli M, Berardi D: The socio-economical burden of schizophrenia: a simulation of cost-offset of early intervention program in Italy. Eur Psychiatry. 2009, 24 (1): 11-16. 10.1016/j.eurpsy.2008.07.009.CrossRefPubMed
54.
Palazzolo J, Brousse G, Favre P, Llorca PM: The information of the schizophrenic patient: actuality. Encephale. 2005, 31 (2): 227-234. 10.1016/S0013-7006(05)82389-9.CrossRefPubMed
55.
van Os J, Kapur S: Schizophrenia. Lancet. 2009, 374 (9690): 635-645. 10.1016/S0140-6736(09)60995-8.CrossRefPubMed
56.
Bartels C, Wegrzyn M, Wiedl A, Ackermann V, Ehrenreich H: Practice effects in healthy adults: A longitudinal study on frequent repetitive cognitive testing. BMC Neurosci. 2010, 11:118: 1-12.
57.
Guo X, Zhai J, Wei Q, Twamley EW, Jin H, Fang M, Hu M, Zhao J: Neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: a naturalistic 12-month follow-up study. Neurosci Lett. 2011, 503 (2): 141-146. 10.1016/j.neulet.2011.08.027.CrossRefPubMed
58.
Mazzaglia G, Mantovani LG, Sturkenboom MC, Filippi A, Trifirò G, Cricelli C, Brignoli O, Caputi AP: Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens. 2005, 23 (11): 2093-2100. 10.1097/01.hjh.0000186832.41125.8a.CrossRefPubMed
59.
Knapp M, Chisholm D, Leese M, Amaddeo F, Tansella M, Schene A, Thornicroft G, Vazquez-Barquero JL, Knudsen HC, Becker T: Comparing patterns and costs of schizophrenia care in five European countries: the EPSILON study. European Psychiatric Services: Inputs Linked to Outcome Domains and Needs. Acta Psychiatr Scand. 2002, 105: 42-54. 10.1034/j.1600-0447.2002._10310.x.CrossRefPubMed
Metadata
Title
Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study
Authors
Paolo A Cortesi
Claudio Mencacci
Ferrannini Luigi
Elvezio Pirfo
Patrizia Berto
Miriam CJM Sturkenboom
Fabiana L Lopes
Maria G Giustra
Lorenzo G Mantovani
Luciana Scalone
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2013
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/1471-244X-13-98

Other articles of this Issue 1/2013

BMC Psychiatry 1/2013 Go to the issue

Research article

Dissociation of understanding from applying others’ false beliefs in remitted schizophrenia: evidence from a computerized referential communication task

Research article

The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial

Research article

Temperamental factors predict long-term modifications of eating disorders after treatment

Research article

Conformance to schizophrenia treatment guidelines in North West-Bank, Palestine: focus on antipsychotic dosing and polytherapy

Study protocol

Follow up of patients who start treatment with antidepressants: treatment satisfaction, treatment compliance, efficacy and safety

Research article

Association between vitamin b12 levels and melancholic depressive symptoms: a Finnish population-based study